![The Agile Brand with Greg Kihlström® podcast artwork](https://cdn.player.fm/images/25641206/series/oilf68jgHPTH2oAn/32.jpg 32w, https://cdn.player.fm/images/25641206/series/oilf68jgHPTH2oAn/64.jpg 64w, https://cdn.player.fm/images/25641206/series/oilf68jgHPTH2oAn/128.jpg 128w, https://cdn.player.fm/images/25641206/series/oilf68jgHPTH2oAn/256.jpg 256w, https://cdn.player.fm/images/25641206/series/oilf68jgHPTH2oAn/512.jpg 512w)
![The Agile Brand with Greg Kihlström® podcast artwork](/static/images/64pixel.png)
In this edition, PALADIN study navigates IOP-lowering surgery in DME patients, small-molecule eye drop well-tolerated as treatment for retinal vascular diseases and more. Read the full coverage here:
PALADIN study: Navigating IOP-lowering surgery in DME patients for optimal outcomes
Small-molecule eye drop safe, well-tolerated as treatment for retinal vascular diseases
VIDEO: Reduction of vascular leakage, hyperreflective foci greater with faricimab
VIDEO: Real-world study shows durability of fluocinolone acetonide implant in DME
Early safety, efficacy results positive for Restoret in DME, wet AMD
References:
Chin Yee DS, et al. Outcomes in eyes requiring IOP-lowering surgery after treatment with the 0.19-mg fluocinolone acetonide implant for DME: The PALADIN study. Presented at: American Academy of Ophthalmology meeting; Nov. 3-6, 2023; San Francisco.
Graff JM. Biomarkers for vascular stability and inflammation demonstrate the benefit of dual Ang-2/VEGF-A inhibition with faricimab phase 3 trials in DME. Presented at: Retina 2024; Jan. 13-19, 2024; Wailea, Hawaii.
Minaker S. The 0.19mg fluocinolone acetonide (FAc) implant reduces the recurrence of edema by providing long-term control of retinal thickness variability in patients with DME: The 3-year PALADIN study. Presented at: Retina 2024; Jan. 13-19, 2024; Wailea, Hawaii.
121 afleveringen
In this edition, PALADIN study navigates IOP-lowering surgery in DME patients, small-molecule eye drop well-tolerated as treatment for retinal vascular diseases and more. Read the full coverage here:
PALADIN study: Navigating IOP-lowering surgery in DME patients for optimal outcomes
Small-molecule eye drop safe, well-tolerated as treatment for retinal vascular diseases
VIDEO: Reduction of vascular leakage, hyperreflective foci greater with faricimab
VIDEO: Real-world study shows durability of fluocinolone acetonide implant in DME
Early safety, efficacy results positive for Restoret in DME, wet AMD
References:
Chin Yee DS, et al. Outcomes in eyes requiring IOP-lowering surgery after treatment with the 0.19-mg fluocinolone acetonide implant for DME: The PALADIN study. Presented at: American Academy of Ophthalmology meeting; Nov. 3-6, 2023; San Francisco.
Graff JM. Biomarkers for vascular stability and inflammation demonstrate the benefit of dual Ang-2/VEGF-A inhibition with faricimab phase 3 trials in DME. Presented at: Retina 2024; Jan. 13-19, 2024; Wailea, Hawaii.
Minaker S. The 0.19mg fluocinolone acetonide (FAc) implant reduces the recurrence of edema by providing long-term control of retinal thickness variability in patients with DME: The 3-year PALADIN study. Presented at: Retina 2024; Jan. 13-19, 2024; Wailea, Hawaii.
121 afleveringen
Player FM scant het web op podcasts van hoge kwaliteit waarvan u nu kunt genieten. Het is de beste podcast-app en werkt op Android, iPhone en internet. Aanmelden om abonnementen op verschillende apparaten te synchroniseren.